RE:RE:RE:GSK drops the development of engineered cell therapy November 09, 2022 - GSK's engineered cell therapy world continues to collapse - this time on the news on Adaptimmune's allogeneic cell therapy program change as reported below today.
"Adaptimmune’s allogeneic MAGE-A4 program seemed to be near the finish line, with the company’s UK manufacturing facility almost done. The plan at the time was for the cell therapy to be ready for trial applications by next year.
But that timeline is now up in flames. The company announced Tuesday that it's decided to switch up the cell line used for the off-the-shelf therapy after a “chromosomal abnormality” was identified in the original batch. That move has pushed back the expected clinical trial readiness of the program by two years, now slated for 2025. "
https://www.fiercebiotech.com/biotech/adaptimmune-lay-30-its-staff-allogeneic-ambitions-stunted-cell-line-change